Matthew T. Wiley
CIK 1759703 · Chief Commercial Officer · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$7.33M
Companies
6
Total Filings
35
Lifetime Open-Market Net
-$85.1K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DFTX | Chief Commercial Officer | 174,633 | $41.96 | $7.33M | -$129.1K | 3 | 2026-06-26 |
| BTAI | Chief Commercial Officer | 1,580 | $0.84 | $1.3K | -$6.6K | 8 | 2025-04-01 |
| Definium Therapeutics, Inc. (MNMD) Delisted | Chief Commercial Officer | — | $15.00 | — | $0 | 1 | 2025-03-18 |
| VYNE | Chief Commercial Officer | 121 | $28.56 | $3.5K | $0 | 6 | 2021-07-02 |
| VYNE Therapeutics Inc. (MNLO) Delisted | Chief Commercial Officer | 352,425 | — | — | $0 | 5 | 2020-07-02 |
| Foamix Pharmaceuticals Ltd. (FOMX) Delisted | Chief Commercial Officer | 114,074 | — | — | $50.5K | 6 | 2020-03-03 |
Recent Filings · Page 3 of 4
35 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-01-05 | VYNE | Tax (F) | −1,541 | -$2.4K | EDGAR |
| 2020-12-02 | VYNE | Grant (A) | +7,838 | $11.3K | EDGAR |
| 2020-10-02 | VYNE | Tax (F) | −1,541 | -$2.6K | EDGAR |
| 2020-07-02 | VYNE Therapeutics Inc. (MNLO) Delisted | Tax (F) | −1,541 | -$2.7K | EDGAR |
| 2020-05-08 | VYNE Therapeutics Inc. (MNLO) Delisted | Grant (A) | +150,000 | $0 | EDGAR |
| 2020-04-07 | VYNE Therapeutics Inc. (MNLO) Delisted | Mixed | +136,916 | -$1.3K | EDGAR |
| 2020-04-02 | VYNE Therapeutics Inc. (MNLO) Delisted | Tax (F) | −525 | -$1.4K | EDGAR |
| 2020-03-11 | VYNE Therapeutics Inc. (MNLO) Delisted | Grant (A) | +67,576 | $0 | EDGAR |
| 2020-03-11 | — | Disp (D) | −114,074 | $0 | |
| 2020-03-03 | Foamix Pharmaceuticals Ltd. (FOMX) Delisted | Grant (A) | +1,993 | $5.3K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.